On February 23, 2021, the Company consummated its Initial Public Offering of 34,500,000 Units at a price of $10.00 per Unit, including 4,500,000 Units as a result of the underwriter’s partial exercise of its over-allotment option, generating gross proceeds of $345,000,000. On the Initial Public Offering Closing Date, we completed the private sale of an aggregate of 5,933,333 Private Placement Warrants, each exercisable to purchase one share of Common Stock at $11.50 per share, to our Sponsor, at a price of $1.50 per Private Placement Warrant, generating gross proceeds, before expenses, of $8,900,000. After deducting the underwriting discounts and commissions (excluding the Deferred Discount, which amount will be payable upon consummation of the Business Combination, if consummated) and the estimated offering expenses, the total net proceeds from our Public Offering and the sale of the Private Placement Warrants were $346,464,342, of which $345,000,000 (or $10.00 per share sold in the Initial Public Offering) was placed in the Trust Account. The amount of proceeds not deposited in the Trust Account on February 23, 2021 was $770,292 at the closing of our Public Offering. Interest earned on the funds held in the Trust Account may be released to us to fund our Regulatory Withdrawals, for a maximum of 24 months and/or additional amounts necessary to pay our franchise and income taxes.
For the nine months ended September 30, 2022, net cash used in operating activities was $908,699. Net income of $11,015,318 was affected by interest earned on marketable securities held in the Trust Account of $2,078,248, change in fair value of our derivative liabilities of $10,074,166, non-cash change in fair value of the convertible promissory note of $34,726. Changes in operating assets and liabilities provided $263,123 of cash for operating activities.
For the nine months ended September 30, 2021, net cash used in operating activities was $1,586,495. Net income of $5,315,873 was affected by interest earned on marketable securities held in the Trust Account of $12,561, change in fair value of our derivative liabilities of $8,154,000, fair value of private warrant liability in excess of proceeds of $771,333, change in fair value of convertible promissory note – related party of $29,648 and offering costs attributable to warrant liabilities of $645,069. Changes in operating assets and liabilities used $181,857 of cash for operating activities.
At September 30, 2022, we had cash held outside of the Trust Account of approximately $152,365, which is available to fund our working capital requirements. Additionally, interest earned on the funds held in the Trust Account may be released to us to fund our Regulatory Withdrawals, for a maximum of 24 months and/or additional amounts necessary to pay our franchise and income taxes. At September 30, 2022, the Company had current liabilities of $439,952 and working capital of $597,494.
We intend to use substantially all of the funds held in the Trust Account, including interest (which interest shall be net of Regulatory Withdrawals and taxes payable) to consummate our Business Combination. Moreover, we may need to obtain additional financing either to complete a Business Combination or because we become obligated to redeem a significant number of shares of our Common Stock upon completion of a Business Combination. Subject to compliance with applicable securities laws, we would only complete such financing simultaneously with the completion of our Business Combination. If we are unable to complete our Business Combination because we do not have sufficient funds available to us, we will be forced to cease operations and liquidate the Trust Account. In addition, following our Business Combination, if cash on hand is insufficient, we may need to obtain additional financing in order to meet our obligations. To the extent that our capital stock or debt is used, in whole or in part, as consideration to consummate our Business Combination, the remaining proceeds held in our Trust Account, if any, will be used as working capital to finance the operations of the target business or businesses, make other acquisitions and pursue our growth strategy.
On September 8, 2021, the Sponsor agreed to loan us an aggregate of up to $2,000,000 pursuant to a new promissory note (the “Working Capital Loan”). The Working Capital Loan is non-interest bearing and payable upon consummation of our initial Business Combination. At the lender’s discretion, the Working Capital Loan may be repayable in warrants of the post Business Combination entity at a price of $1.50 per warrant. At September 30, 2022, there was $1,350,000 of borrowings under the Working Capital Loan. This note was valued using the fair value method as discussed in Note 9. The fair value of the note as of September 30, 2022, was $1,328,124, which resulted in an increase in fair value of the convertible promissory note of $3,649 and a decrease in fair value of $34,726 recorded in the statement of operations for the three and nine months ended September 30, 2022, respectively.